Efficacy of Diane 35 vs Diane 35 plus metformin on polycystic ovarian syndrome women under comprehensive management

doi:10.3969/j.issn.1006-7795.2014.04.005

Abstract

Abstract:

Objective To provide theoretical basis of standardized management and treatment for polycystic ovarian syndrome(PCOS) patients through the study of Diane 35 vs Diane 35 plus metformin on PCOS women under comprehensive management. Methods Sixty patients with PCOS were randomly divided into two groups, Diane-35-only group and Diane-35 plus metformin(the combination) group, each with 30 cases. Their resting-energy-consumption and body-composition-measurement on movement functionality were analyzed to offer individualized nutrition and exercise guidance. Three Diane-35 cycles were administered; metformin was added in one group. We selected the data of patients' height, weight, waist circumference, hip circumference, body fat percentage, acne score, hirsutism score; serum hormone level were tested between 2nd and 5th days of menstrual cycle, such as follicle-stimulating hormone, luteinizing hormone, testosterone, blood glucose, blood lipids, insulin, etc. Results 1 After three months' treatment, body mass index, acne score, LH levels and T levels dropped in both groups, while HDL-C concentration elevated, the difference was statistically significant(P<0.05); the hairy score decreased slightly(P>0.05); total cholesterol and triglycerides concentration elevated(P>0.05). 2 After three months' treatment, the body fat content, fasting glucose and insulin resistance index in combined treatment group decreased, the difference was statistically significant(P<0.05). 3 After three months' treatment, fasting blood sugar was elevated and fasting insulin concentration dropped in Diane-35 treatment group(P>0.05). 4 The body mass index, fasting blood glucose changes were significant different between two groups(P<0.05), while the rest indicators were not significantly different(P>0.05). Conclusion Under the individualized nutrition and exercise guidance, Diane-35 only group or Diane-35 plus metformin group could both effectively reduce serum testosterone levels, improve acne symptoms, but not hirsutism. The combination group can reduce the fat content in patients with PCOS, improve glucose and lipid metabolism, and Diane-35 alone does not worsen glucose and lipid metabolism in patients with PCOS.

Key words: polycystic ovary syndrome, Diane 35, metformin, comprehensive treatment

CLC Number:

R711

Wu Hongqin, Ruan Xiangyan, Lu Yongjun, Tian Xuanxuan, Zhang Ying, Liu Yulan, Zhen Jie, Diethelm Wallwiener, Alfred O. Mueck. Efficacy of Diane 35 vs Diane 35 plus metformin on polycystic ovarian syndrome women under comprehensive management[J]. Journal of Capital Medical University, 2014, 35(4): 407-413.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2014.04.005

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2014/V35/I4/407

References

[1] Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report[J]. Fertil Steril, 2009,91(2):456-488.
[2] Fauser B C, Tarlatzis B C, Rebar R W, et al. Consensus on women's health aspects of polycystic ovary syndrome(PCOS): the Amsterdam ESHRE/ ASRM-Sponsored 3rd PCOS Consensus Workshop Group[J]. Fertil Steril, 2012,97(1):28-38.
[3] 卢永军,阮祥燕,田玄玄,等.多囊卵巢综合征综合治疗疗效的评价[J].首都医科大学学报,2013,34(4):525-529.
[4] Calaf J, López E, Millet A, et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial[J]. J Clin Endocrinol Metab, 2007,92(9):3446-3452.
[5] Demircay Z, Kus S, Sur H. Predictive factors for acne flare during isotretinoin treatment[J]. Eur J Dermatol, 2008,18(4):452-456.
[6] Thessalonkik ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome[J]. Fertil Steril, 2008,89(3):505-522.
[7] Baptiste C G, Battista M C, Trottier A, et al. Insulin and hyperandrogenism in women with polycystic ovary syndrome[J]. J Steroid Biochem Mol Biol, 2010,122(1-3):42-52.
[8] Domecq J P, Prutsky G, Mullan R J, et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2013,98(12):4655-4663.
[9] Yildiz B O, Knochenhauer E S, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2008,93(1):162-168.
[10] Svendsen P F, Nilas L, Norgaard K, et al. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome[J]. Hum Reprod, 2008,23(9):2113-2121.
[11] Lord J, Thomas R, Fox B, et al. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome[J]. BJOG, 2006,113(10):1203-1209.
[12] Gallo M F, Lopez L M, Grimes D A,et al. Combination contraceptives: effects on weight[J]. Cochrane Database Syst Rev, 2014,1:CD003987.
[13] Glintborg D, Altinok M L, Mumm H, et al. Body composition is improved during 12 months treatment with metformin alone or combined with oral contraceptives compared to treatment with oral contraceptives in polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2014,17:jc20141135.
[14] Tan J. Hormonal treatment of acne: review of current best evidence[J]. J Cutan Med Surg, 2004,8 Suppl 4:11-15.
[15] 党慧敏.达英-35联合二甲双胍治疗多囊巢综合征疗效观察.大连:大连医科大学,2012.
[16] Caruso S, Cianci S, Malandrino C, et al. Hyperandrogenic women treated with a continuous-regimen oral contraceptive[J]. Eur J Obstet Gynecol Reprod Biol, 2013,171(2):307-310.
[17] Kahraman K, Sükür Y E, Atabekoglu C S, et al. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial[J]. Arch Gynecol Obstet, 2014,.
[18] Prelević G M, Würzburger M I, Balint-Perić L, et al. Effects of a low-dose estrogen-antiandrogen combination(Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome[J]. Gynecol Endocrinol, 1989,3(4):269-280.
[19] Rautio K, Tapanainen J S, Ruokonen A, et al. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome[J]. Eur J Endocrinol, 2005,152(2):269-275.
[20] Wu J, Zhu Y, Jiang Y, et al. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome[J]. Gynecol Endocrinol, 2008,24(7):392-398.
[21] Orbetsova M, Kamenov Z, Kolarov G, et al. Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome(PCOS) in order to determine therapeutic strategy[J]. Akush Ginekol(Sofiia), 2006,45(7):16-28.
[22] Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study[J]. Hum Reprod, 2002,17(7):1729-1737.